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Abstract
Background: Intestinal-type sinonasal adenocarcinomas (ITACs) are aggressive malignancies related to wood
dust and leather exposure. ITACs are generally associated with advanced stage at presentation due to the insidious
growth pattern and non-specific symptoms. Therefore, biomarkers that can detect the switch from the benign disease to
malignancy are needed. Essential for tumour growth, angiogenesis is an important step in tumour development and
progression. This process is strictly regulated, and MiR-126 considered its master modulator.
Methods: We have investigated MiR-126 levels in ITACs and compared them to benign sinonasal lesions, such as
sinonasal-inverted papillomas (SIPs) and inflammatory polyps (NIPs). The tumour-suppressive functions of MiR-126 were
also evaluated.
Results: We found that MiR-126 can significantly distinguish malignancy from benign nasal forms. The low levels of MiR-
126 in ITACs point to its role in tumour progression. In this context, restoration of MiR-126 induced metabolic changes,
and inhibited cell growth and the tumorigenic potential of MNSC cells.
Conclusions: We report that MiR-126 delivered via exosomes from endothelial cells promotes anti-tumour responses.
This paracrine transfer of MiRs may represent a new approach towards MiR-based therapy.
Keywords: Intestinal-type sinonasal adenocarcinomas, Sinonasal-inverted papillomas, Inflammatory polyps, Biomarker,
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Background
Cancers of the nasal cavity and the paranasal sinuses, re-
ferred to as sinonasal cancers (SNCs), are associated
with occupational exposure to wood, leather and nickel
particles that are reported as risk factors for the develop-
ment of these tumours [1]. SNCs account for 0.2% of all
primary malignant neoplasms, with an incidence of 0.1–
1.4 new cases/year/100.000 subjects. Around 8–25% of
all SNCs are intestinal-type adenocarcinomas (ITACs),
which are malignant epithelial tumours related to wood
dust exposure. This type of cancer is characterized by
frequent local recurrences, low incidence of distal me-
tastases, and overall mortality of approximately 53%.
The clinical stage and histology of the tumour have a
considerable impact on survival. Surgery with or with-
out radiotherapy represents the preferred treatment of
these tumours. In spite of aggressive surgery and
high-dose radiation therapy, the low rate of long-term
survival of patients with SNC is disappointing [2].
Certain benign forms of the sinonasal pathology, such
as sinonasal-inverted papillomas (SIPs), can progress
to sinonasal squamous cell carcinoma (SNSCC), and
the incidence of the malignant switch in individual
series of SIPs was reported as 5–10% [3, 4].
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The molecular mechanism involved in the pathogen-
esis of ITACs is largely unknown [5, 6]. Chronic inflam-
matory states and angiogenesis have been linked to the
development of malignancy [7]. Angiogenesis is an im-
portant process in tumour progression, the vascular
endothelial growth factor (VEGF) being one of the key
drivers of both physiological and pathological blood ves-
sel formation. VEGF, as well as angiomotin, a protein
that regulates tubule formation, are significantly in-
creased in SIP, which was suggested to contribute to its
progression by promoting angiogenesis [8, 9]. Angiogen-
esis has been also related to the pathogenesis and prog-
nosis of chronic rhinosinusitis with nasal polyposis [10].
Nasal inflammatory polyps (NIPs) include mucosal epi-
thelial hyperplasia, infiltration of inflammatory cells,
neo-vascularization, and edema [11].
Both angiogenesis and inflammation are processes reg-
ulated by microRNAs (MiRs), such as MiR-126, which is
encoded by intron 7 of the epidermal growth factor-like
protein 7 (EGFL7) gene [12]. MiR-126 is mainly
expressed by endothelial cells (ECs), and plays a critical
role in several human cancers [13]. It has been shown
that MiR-126 inhibits tumour growth by prevention of
cancer cell proliferation, migration, and invasion, but
also by down-regulation of central signal molecules of
cancer cell survival [14–16]. To evaluate the role of
MiR-126 in the malignancy of SNCs, expression and dis-
tribution of MiR-126 were investigated in malignant
ITACs and compared to sinonasal benign neoplasms,
such as SIPs and NIPs. The tumour suppression func-
tion of MiR-126 was also evaluated, supporting its role
as a potential novel cancer suppressor.
Methods
Specimens
Fresh and formalin-fixed paraffin-embedded (FFPE)
tumour tissues and matched adjacent normal epithelium
were obtained from 58 surgically treated patients; 23 of
them were diagnosed with ITACs, 15 with SIPs, and 20
had documented NIPs. All samples were collected from
the archive of the Pathological Anatomy Unit of the
Hospital University of Ancona, and from the Otorhino-
laryngology Department of Budrio-Metropolitan Hos-
pital Bologna, Italy. The clinical data included
information on gender, age, histology, staging according
to the TNM classification (UICC 2009), therapeutic
protocol and the follow-up conditions.
Whole blood was collected from ITAC patients (n =
13) at the time of clinical examination and serum was
prepared. The control group consisted of 19 healthy sub-
jects recruited at the clinical of Occupational Medicine,
Polytechnic University of Marche, Ancona, Italy. None
of them had ever been occupationally exposed to wood
and leather dust, as documented by their occupational
histories.
RNA, circulating MiR-126 isolation and quantitative RT-
PCR
Total RNA from cultured cells and tissue samples (10–
100 μg) was obtained using the RNeasy Mini Kit
(Qiagen) and the RecoverAll total nucleic acid isolation
kit (Ambion), respectively, according to the manufac-
turer’s instructions. MiR-126, IRS1, VEGF-A, SOX-2 and
EGFL7 first-strand cDNA was synthesized using the
High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Quantitative RT-PCR (qPCR) was per-
formed using the TaqMan Gene Expression Master Mix
(Applied Biosystems) with U6 and GAPDH as the
housekeeping gene for the MiR and the genes,
respectively. qPCR assays were performed using the
Mastercycler EP Realplex instruments (Eppendorf ) and
results expressed as relative level (2-ΔCT), and fold
changes (2-ΔΔCT). For circulating MiR-126 detection,
RNA was isolated from 250 μl of diluted serum (1:10),
or from the exosomal fraction (20 μg protein) and
MiR-126 was detected as previously described [17, 18].
Bisulphite modification and genomic sequencing
The methylation status of CpG dinucleotides close to
the EGFL7 T2 promoter was analysed. The bisulphite se-
quencing assay was performed using 1 mg of
bisulphite-treated genomic DNA from malignant tissue
and adjacent non-cancerous tissue of seven patients with
SNC. Bisulphite conversion was performed using the EZ
DNA Methylation™ Kit (Zyno Research, Euroclone) ac-
cording to the manufacturer’s instructions. Fragments of
interest were amplified using the following specific pri-
mer pairs designed with the Primer3 software, i.e. for-
ward: 5′-TGA TTT AGT GAT TTC GGT GAG G-3′;
reverse, 5′-AAC CCT TTA CTA ACT TTC AAA
CCC-3′. PCR products were gel-purified by means of
the Wizard SV gel and PCR Clean-up kit (Promega) or
the FastGene Gel/PCR Extraction Kit (Nippon Genetics),
and sequenced using the Reverse primer (5′-AAC CCT
TTA CTA ACT TTC AAA CCC-3′) to analyse the
DNA methylation status. Sequencing of purified PCR
products was carried out using automated DNA se-
quencers at Eurofins MWG Operon (Germany). All se-
quences were visualized with BioEdit Sequence
Alignment Editor 7 [19] and aligned with the ClustalW
option included in this software.
Cell culture
Malignant nasal squamous cell carcinoma from the
pleural effusion (MNSC, RPMI 2650) and fibroblasts
(IMR-90) were obtained from the ATCC and grown in
the RPMI-1640 and DMEM medium, respectively, with
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10% FBS, 1% penicillin and 10% streptomycin (Life
Technologies). Human umbilical vein endothelial cells
(HUVECs) obtained from GIBCO (Life Technologies)
were grown in Medium 200 with the large vessel endo-
thelial supplement (LVES, Life Technologies). Cells were
maintained at 37 °C and 5% CO2, and cultured for not
more than six passages within 1 month after resuscita-
tion and periodically checked for the absence of myco-
plasma contamination using the PCR Mycoplasma Test.
Cell authentication was performed using the PowerPlex
Fusion 6C System (Promega, Fitchburg, WI).
Exosome isolation and exosome uptake
Exosomes were isolated from HUVECs cultured in
exosome-depleted serum-containing medium as previ-
ously described [18]. For exosome uptake assay, isolated
exosomes were stained with PKH-67 (20 μM, 4 min;
Sigma), a probe used to label lipids on membrane
surface of exosomes. After washing in PBS,
PKH-26-labelled exosomes were placed in conditioned
medium of MNSC cells, and uptake was periodically
analysed by flow cytometry (FACS Calibur, BD). Alterna-
tively, uptake was assessed after 4 h incubation by fluor-
escent microscopy (Axiocam MRc5 Zeiss).
Ectopic MiR-126 expression
MNSC cells (2 × 104 per well in a 24 well plate) were sta-
bly transfected with the pCMV-MiR plasmid carrying
the MiR-126 sequence 5’-UCG UAC CGU GAG UAA
UAA UGC G-3′ (OriGene) using the TransIT-LT1 re-
agent (Mirus). Selection of transfected cells was per-
formed using G418 (0.6 mg/ml; Sigma) added to the cell
culture medium after transfection. G418-resistant clones
were analysed for MiR-126 expression and maintained in
the RPMI media with 0.6 mg/ml G418. Alternatively,
cells were transiently transfected with the MiR-126 mi-
metic (MISSION® microRNA Mimic; Sigma) using High
Perfect Transfection reagent (Qiagen). MiR-126 function
was blocked with the anti-sense oligonucleotide 5’-GCA
UUA UUA CUC ACG GUA CGA-3′ (IDT); scrambled
sequences were used as a control.
Acid vesicles and red oil O staining of lipids
Acid vesicles (AVs) in MNSC cells and their
MiR-126-transfected counterparts were evaluated by
acridine orange (AO) staining. Cells were seeded on
coverslips in a 6-well plate, allowed to attach overnight,
incubated with 5 mg/ml AO for 30 min at 37 °C. For
detection of lipid droplets (LDs), cells grown on cover-
slips were fixed in 70% (v/v) cold ethanol and stained
with the Oil Red O solution in 60% (v/v) isopropanol.
Cells were analysed using fluorescent and optical mi-
croscopy, respectively (Zeiss, Axiocam MRC5; magnifi-
cation 40× or 60×).
Migration and cell proliferation assay
Migration assays were performed after seeding cells in
the 12-well plate allowed to reach confluence and
treated with mitomycin-C (5 μg/ml, 3 h; Sigma) to
block the cell cycle. Cells were wounded by scratch-
ing with sterile pipette tip and supplemented with
exosomes isolated from HUVECs (20 μg/ml). Migra-
tion was quantified as wound-healing percentage of
the cells determined by the ratio of the ‘wound width’
at 72 h time and the wound width at 0 h. The MTT
assay (Sigma) was performed and Ki67-positive cells
were estimated as a measure of cell proliferation.
MNSC cells and the MiR-126 plasmid- or
mimetic-transfected cells (3 × 104 cells/well in
96-well-plate) were incubated at different time points
and cell viability evaluated. Alternatively, cell viability
was analysed in MNSC cells exposed to exosomes
isolated from HUVECs. Ten microliters of MTT
(5 mg/ml) was added to each well and after 3 h incu-
bation, the crystals prodused were dissolved in isopro-
panol and absorbance read at 550 nm in an ELISA
plate reader (Sunrise, Tecan). The results were
expressed as relative change with respect to the con-
trols set as 100%. Proliferation was assessed in perme-
abilized cells using the anti-Ki67 IgG and
fluorescence microscopy (Zeiss; Axiocam MRc5, mag-
nification 60×). The proliferation index was expressed
as a percentage of Ki67-positive cells.
Glucose uptake and glucose, ATP and lactate detection
MNSC cells were seeded in 96-well black-bottom plates
(3 × 104 cells per well) in low glucose (1 g/l) DMEM at
5% CO2 and 37 °C. After overnight incubation, the cells
were treated with 2-nitrobenzodeoxyglucose (2-NBDG,
50 μM) for 30 min. The level of fluorescence intensity
was evaluated at 550/590 nm using a fluorescence plate
reader (Infinite F200 PRO, Tecan). Glucose, lactate and
intracellular ATP were evaluated in the presence and ab-
sence of rotenone (20 μM, 5 h) and 2-deox-glucose
(2DG; 5 mM, 5 h) using commercial kits (Abcam) ac-
cording to the manufacturer’s protocol. The results were
normalized to the total protein content.
Mitochondrial reducing activity
Mitochondrial reducing activity (MRA) was assessed in
MiR-126-transfected MNSC cells and their parental
counterparts as the reduction of resazurin based on the
mitochondrial metabolic activity [15, 20]. Cells were in-
cubated with resazurin (6 μM) and fluorescence intensity
read at 0–240 min in a fluorescence plate reader (Infin-
ite F200 PRO). The results were normalized to the total
protein detected using the Bradford assay (Sigma).
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Colony-forming assay
MNSC cells and their MiR-126 plasmid-transfected
counterparts were seeded in 0.35% low melting point
agar overlaid with 0.7% low melting point agar in
24-well plates and cultured at 37 °C and 5% CO2 for
1 month. Every 7 days, 0.5 ml of fresh medium was
added to each well, the number of colonies counted, and
the size and the shape evaluated after 3 weeks. In
addition, MNSC colonies in soft-agar were treated with
exosomes from HUVECs (20 μg/ml) each week, and
their size and shape evaluated after a 3-week treatment.
Alternatively, MNSC cells (103 cells per well in 24-well
plate) were treated with the MiR-126 mimetic (100 nM),
and colony formation was evaluated. Colonies were fixed
with formalin (4.0% v/v), stained with crystal violet (0.5%
w/v), and counted using a stereomicroscope.
Triple co-culture model
A 3-μm trans-well insert (Costar 3452; Corning,) was
first plated with 105 cultured IMR90 cells in an inverted
position. After 6 h of incubation, inserts were flipped
over and placed into a six-well trans-well plate, where
3 × 105 HUVEC cells were loaded on the other side of
the insert and cultured for 24 h. This HUVEC-IMR90
pre-coated trans-well inserts were then placed into an-
other six-well trans-well plate, where 2 × 105 malignant
nasal-septum carcinoma (MNSC) cells had been plated.
Exosome-exposed HUVECs (50 μg/ml) were added to
the triple co-culture system, and after 48 h of incubation
MNSC cells were collected.
Western blot analysis
Cells were lysed in the RIPA buffer containing Na3VO4
(1 mM) and protease inhibitors (1 μg/ml). The cell lysate
proteins were separated using SDS-PAGE and trans-
ferred onto nitrocellulose membranes (Protran). After
blocking with 5% non-fat milk in PBS-Tween (0.1%), the
membranes were incubated with antibodies against IRS1
(Bethyl), phospho-p38 MAPK, p38-MAPK,
phospho-ERK1/2 and ERK1/2 (all Cell Signaling).
β-actin was used as a loading control. After incubation
with the HRP-conjugated secondary IgG (Sigma), blots
were developed using the ECL detection system (Pierce
Biotechnology). The band intensities were visualized and
quantified with ChemiDoc using the Quantity One soft-
ware (BioRad Laboratories).
Statistical analysis
Data are expressed as mean values ± standard deviation
(SD). Comparisons among groups of data were per-
formed using one-way analysis of variance (ANOVA),
with Tukey post-hoc analysis. A p-value ≤0.05 was con-
sidered significant. All statistical analyses were per-
formed using the SPSS software.
Results
MiR-126 level and epigenetic regulation
There were no significant differences in age and gender
among the studied groups, as documented in Table 1
summarising the demographic and pathological charac-
teristics of the subjects. MiR-126 levels were significantly
decreased in ITAC tissue (Fig. 1a), while MiR-126 in SIP
and NIP tissues were strongly increased compared to
the matched normal mucosa (Fig. 1a, b). Low level of
MiR-126 was also found in serum of patients affected by
ITACs (Fig. 1c), which significantly distinguished pa-
tients with ITACs from healthy controls with a sensitiv-
ity and specificity of 80% and 70% (Fig. 1d).
The MiR-126 gene is located in an intron of a
protein-coding gene, EGFL7, and its expression was pre-
viously reported to be closely correlated with the T2
EGFL7 transcript [21]. To explore whether epigenetic
regulation of the host EGFL7 gene could directly affect
MiR-126 expression, the T2 promoter methylation was
investigated in malignant and adjacent non-cancerous
tissues obtained from six surgical samples of ITAC pa-
tients. Highly methylated T2 promoter was found
in ITAC patient tissues with down regulation of EGFL7
gene expression (Fig. 2a, b). Correlation between EGFL7
promoter methylation and reduced expression of both
MiR-126 and its host gene EGFL7 was found (Fig. 2c).
Despite the fact that EGFL7 T2 promoter methylation
above 40% resulted in a marked reduction of EGFL7
gene expression in tumour tissues, no association with
MiR-126 down-regulation was found (Fig. 2d). These re-
sults indicate that other factors in addition to epigenetic
changes of the EGFL7 T2 promoter are involved in
MiR-126 expression during cancer progression.
Ectopic expression of MiR-126 suppresses tumour growth
and affects cell metabolism
Given that MiR-126 was found down-regulated in malig-
nant tissues, we hypothesised that its increased expres-
sion could affect cancer development and progression.
The development of sinonasal tumours, such as SNSCC
and, especially ITAC, is strongly associated with occupa-
tional exposure, possibly through tumorigenic pathways
of chronic inflammation. The SNSCC and ITAC have
aneuploid genomes harbouring multiple genetic aberra-
tions; we thus reasoned that both histotypes showed
comparable response to miRNA treatment. According to
the above, the MNSC cell line was used as an in vitro
model for sinonasal tumours. Higher levels of MiR-126
following its overexpression and also transfection with
the MiR mimetic resulted in a dose-dependent inhibition
of MNSC cell growth (Additional file 1: Figure S1A).
AntiMiR-126 reversed these effects, suggesting that the
observed inhibition of cell proliferation is dependent on
MiR-126 (Additional file 1: Figure S1B).
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Loss of malignancy was also observed in MiR-126-
transfected MNSC cells. Ectopic expression of MiR-126
resulted in inhibition of colony formation, which was
associated with metabolic changes. Glucose uptake and
intracellular glucose, ATP and lactate were evaluated by
inhibiting oxidative phosphorylation (OXPHOS) with
rotenone or glycolysis with 2DG. MiR-126 alters glucose
homeostasis by inhibiting glucose uptake and shifting
the metabolism from glycolysis to OXPHOS. Differently
to parental cell, where glucose is mainly metabolised by
glycolysis, glucose was found to be processed via both
OXPHOS and glycolysis in MiR-126-transfected MNSC
cells resulting in lower ATP and lactate production as-
sociated with low rate of mitochondrial reducing activ-
ity (Fig. 3a, e). The metabolic shift was associated with
morphological changes, acid vesicle formation and
accumulation of lipid droplets (LDs) (Additional file 2:
Figure S2).
Exosomes with MiR-126 reduce cell growth and suppress
malignancy
Exosomal transfer of MiR-126 may have functional rele-
vance. Endothelial cells release exosomes enriched in
MiR-126 that are taken up by ECs themselves (paracrine
signalling) or that translocate to other compartments to
modulate the downstream intercellular signalling media-
tors [22, 23]. To evaluate the uptake of HUVEC-derived
exosome by MNSC cells, a quantitative flow cytometric
assay was performed. Fluorophore-labelled exosomes
from HUVECs were administered at increasing
Table 1 Demographic and pathological characteristics of the study population
Biopsy-samples Serum-samples
ITACs
(n = 23)
SIPs
(n = 15)
NIPs
(n = 20)
ITACs
(n = 13)
CTRL
(n = 19)
Age (years) 70.1 ± 11.6 57.4 ± 18.0 57.5 ± 15.4 66.2 ± 11.6 40.5 ± 11.4
Gender (M/F %) 91/9 67/33 85/15 92/8 84/16
Smoking (yes/no %) – – – 58/42 47/53
ITACs Intestinal-type adenocarcinomas, SIPs sinonasal inverted papillomas, NIPs nasal inflammatory Polyps
Fig. 1 Levels of MiR-126 in tissues and serum of studied populations and its biomarker performance. Box-plots showing MiR-126 levels in
biopsies of normal mucosa (M), Intestinal-type adenocarcinomas (ITACs), sinonasal inverted papillomas (SIPs) and nasal inflammatory polyps (NIPs)
shown as relative expression (2-ΔCt) (a) or fold-change (b). c Relative expression of MiR-126 in serum of patients with ITACs and in healthy
controls. d Receiver-operating curve (ROC) of serum MiR-126 to differentiate between ITAC patients and control subjects. MiR-126 yielded an AUC
of 0.813 ± 0.064 with 80% sensitivity and 70% specificity in discriminating patients with SNC from healthy subjects, p < 0.0005. *Mucosa versus
ITAC, SIP, and NIP groups, p < 0.05
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concentration, and exosomal uptake by MNSC recipient
cells was evaluated over time. As shown in Fig. 4a, uptake
of exosomes was linear for up to 360 min and 100 μg/ml
of exosome protein. Subsequent transport studies were
carried out using the incubation time of 360 min. MNSC
cells took up EC-derived PKH-67-labelled exosomes in a
time- and concentration-dependent manner (Fig. 4a, b).
As shown by the kinetic analysis, the uptake was rapid,
and exosome internalization was visualized as punctuate
green fluorescence (Fig. 4c). Next, the biological effect of
exosome-delivered MiR-126 in cancer was investigated by
treating MNSC cells with exosomes derived from
HUVECs, and MiR-126 levels and cell proliferation were
evaluated. As shown in Fig. 4d, MiR-126 was up-regulated
compared to untreated MNSC cells, which was associated
with inhibition of cell proliferation. AntiMiR transfection
Fig. 2 Epigenetic regulation of MiR-126 expression via changes in the methylation status of the host gene EGFL7 T2 promoter. a Methylation level
of the EGFL7 promoter in biopsies of non-cancerous mucosa (M) and intestinal-type adenocarcinomas (ITACs). b Expression of EGFL7 in biopsies of
normal mucosa (M) and Intestinal-type adenocarcinomas (ITACs). c EGFL7 gene (left-panel) and MiR-126 (right-panel) expression correlate with the
methylation status of the EGFL7 T2 promoter. MiR-126 and EGFL7 expression was determined by qPCR and normalized to RNU6B RNA and G6PDH,
respectively, in the clinical samples. d EGFL7 gene expression and MiR-126 levels in cancer tissues in relation to the methylation status of the EGFL7
T2 promoter. Methylation percentage was calculated using the bisulphite genomic sequencing results. *Mucosa versus ITACs, p < 0.05
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resulted in MiR-126 down-regulation, with subsequent
increased cell proliferation, pointing to a MiR-126-
specific effect. We found that exosomal MiR-126
inhibited the expression of its gene targets, such as
insulin receptor substrate-1 (IRS1) and VEGF. The
sex-determining region Y-box 2 (SOX2) and EGFL7
were not affected by MiR-126 derived from HUVEC
exosomes, whose expression was markedly induced by
anti-MiR, supporting the notion that both targets
were regulated by MiR-126 acting via a negative feed-
back mechanism (Fig. 4e).
To get additional support for the function of MiR-126
as a tumour suppressor, a triple co-culture model was used.
MNSC cells were co-cultured with fibroblasts (IMR-90)
and HUVECs, and treated with exosomes derived from
HUVECs. After 48 h, MNSC cells were collected and
analysed for MiR-126 and expression of its target genes.
Cell migration and proliferation were also evaluated in the
triple co-culture model after incubation with exosomes
from HUVECs. Downregulation of MiR-126 and
up-regulation of EGFL7 were observed as a result of the
co-culture. Similar to this, decreased expression of
MiR-126 was found following exposure to exosomes de-
rived from HUVECs. However, this treatment resulted in
suppression of VEGF and SOX2 gene expression (Fig. 5a).
As shown in Fig. 5b, MiR-126 delivered via HUVEC-der-
ived exosomes significantly inhibited colony formation
and growth in soft agar, markers of a malignant sta-
tus. Incubation with exosomes induced a slight reduc-
tion of the MAPK/ERK pathway, which was
associated with inhibition of cell migration and prolif-
eration (Fig. 5c, d).
Fig. 3 MiR-126 affects glucose homeostasis and bioenergetic profile. MiR-126-transfected malignant nasal-septum carcinoma (MNSC-126) cells
and their counterparts (parental MNSC cells) were evaluated for glucose uptake (a) using 2-NBDG (50 μM) in low-glucose DMEM, expressed as
mean fluorescent intensity (MFI). Intracellular levels of glucose (b), ATP (c) and lactate (d) were evaluated in the presence of rotenone (20 μM,
5 h) or 2DG (5 mM, 5 h). The mitochondrial reducing activity (MRA) was evaluated by means of the resazurin assay (e). The data shown are mean
values ± S.D. derived from three independent experiments. The symbol “*” indicates significant differences compared with control; the symbol “°”
compared with parental cells
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Discussion
In the present study we found that the angiogenic
MiR-126 may distinguish between malignant and benign
forms, such as SIP and NIP (cf Fig. 1). In particular,
MiR-126, expressed at low levels in ITACs due to
changes in the methylation status of the host gene
EGFL7 T2 promoter (cf Fig. 2), was found up-regulated
in SIP and even more in NIP. Methylation-associated
regulation of MiR-126 and its host gene EGFL7 has been
described in other tumours [24–26]. Although epigenetic
Fig. 4 Exosomal transfer of MiR-126 from endothelial cells inhibits proliferation of malignant nasal-septum carcinoma (MNSC) cells. a Temporal
and dose-dependent kinetics of HUVEC exosome uptake in MNSC cells, and (b) dose-response curve at 360 min. Exosomes (exo) were isolated
from HUVECs grown in the medium supplemented with exosome-free serum. Isolated exosomes were stained with the lipophilic dye PKH-26 and
extensively washed with two subsequent ultracentrifugation spins. Next, MNSC cells were incubated over time with PKH-26-labelled exosomes at
different concentrations (μg/ml). Cell were then washed, trypsinized and their fluorescence analysed by flow cytometry, and the uptake was
expressed as mean fluorescence intensity (MFI). c Representative fluorescence image of uptake of exosomes derived from HUVECs by MNSC cells.
MNSC cells, cultured in exosome-depleted serum, were incubated with PKH-26 -labelled exosomes (20 μg/ml) from HUVECs for 4 h and their
internalization visualized by fluorescent microscope (Zeiss, Axiocam MRc5; magnification 40-60×). The scale bar for all images equals 100 μm. d
MiR-126 levels and cell proliferation of MNSC cells evaluated by the MTT assay after incubated with exosomes (20 μg/ml) isolated from HUVECs in
the presence or absence of antiMiR. e Expression of MiR-126 targets IRS1, VEGF, SOX2, and EGFL7 after incubation of MNSC cells with exosomes
isolated from HUVECs in the presence or absence of antiMiR. The data shown are mean values ± S.D. derived from three independent
experiments. The symbol “*” denotes significant differences between non treated cells (CTRL) and exo-HUVEC treated cells with and without
antiMiR, p < 0.05
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modification is a crucial mechanism for controlling the
expression of miR-126, we did not find a strict relation-
ship between MiR-126 expression and methylation sta-
tus of the host EGFL7 gene in SNC tissues (cf Fig. 2).
There are other factors linked to cancer metabolism or
exosomal delivery from neighbouring cells that may
affect MiR-126 expression [14, 22, 23]. It was suggested
that a cancer stroma cross-talk induced repression of
MiR-126 to facilitate angiogenesis and invasion [27].
MiR-126 is enriched in ECs, modulating the level of di-
verse transcripts that control angiogenesis. Expression
analysis documents increased levels of MiR-126 in highly
Fig. 5 Exosome-delivered MiR-126 from endothelial cells as a treatment of malignant nasal-septum carcinoma (MNSC) cells. a Cancer cell-stromal
cell cross talk. Triple co-culture was performed by layering fibroblasts (IMR-90) and endothelial cells (HUVEC) on two opposite surfaces of trans-well
inserts, and MNSC cells were cultured at the bottom of the trans-well. The co-culture was treated with exosomes from HUVEC (exo-HUVEC, 50 μg/ml),
and after 2 days of treatment MiR-126 level and the expression of its gene targets were evaluated in MNSC cells. b Effect of exosomes
from endothelial cells on colony-forming activity in MNSC cells. The images shown represent 3 months of treatment (magnification 2.5×).
c Immunoblot evaluation of MAPK signalling. MNSC cells in triple co-culture were treated with exo-HUVEC (20 μg/ml), and after 2 days of
incubation evaluated for the expression of IRS1, pERK1/2, ERK1/2, p-p38, p38 (upper-panel). Densitometry evaluation of the bands related
to the level of actin (down-panel). d Representative images of wound healing mobility assay (left-panel) and proliferative index Ki67
staining (right-panel). MNSC cells in triple co-culture were treated with exo-HUVEC (20 μg/ml), and after incubation evaluated for wound-healing
mobility percentage and percentage of Ki67 positive cells. All experiments were carried out in triplicate. The symbol “*” denotes significant differences
between non treated cells (CTRL) and exo-HUVEC treated cells, p < 0.05
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vascularized tissues, such as the heart, liver, and lung.
On the other hand, MiR-126 has been shown to be a
negative modulator of angiogenesis in the eye [28].
There is evidence that MiR-126 contributes to vascular
homeostasis by inhibiting angiogenesis and maintaining
the quiescent endothelial phenotype associated with in-
creased vascular integrity and inhibited proliferation and
motility. MiR-126 up-regulation activates endothelial
progenitor cells (EPCs) and ECs in the case of vascular
injury and/or hypoxia, contributing to vascular healing
and formation of new blood vessels [29]. High level of
MiR-126 induces angiogenesis in non-malignant tissues
by a mechanism that involves MiR-126-induced inhib-
ition of the tumour suppressor SPRED1 [30]. Conversely,
low levels of MiR-126 contribute to the deregulation of
blood vessel formation in tumours, probably by enhan-
cing VEGF expression [31]. These dual pro- and
anti-angiogenic properties make MiR-126 a plausible
biomarker to detect transition from the benign to the
malignant phenotype. This is the case of SIP, which is
characterized by a relatively strong potential for local tis-
sue destruction, high rate of recurrence, and a risk of
carcinomas. The follow-up of patients is critical to diag-
nose local relapse, which often occurs as an early event.
The serious nature of this pathology is linked to its asso-
ciation with carcinomas, which may be diagnosed at the
onset or the recurrence during the follow-up. It is there-
fore imperative to diagnose recurrence of the pathology
in early stages in order to initiate early treatment, espe-
cially in the case of SIP-associated carcinomas [32, 33].
As previously reported, low levels of MiR-126 in can-
cer [12], including SNC, highlight its role in tumour for-
mation and development. In this context, restoration of
MiR-126 induced metabolic changes and inhibited cell
growth and tumorigenesis of cultured MNSC cells (cf
Additional file 1: Figure S1 and Additional file 2: Figure
S2). Cancer cells prefer glycolysis and circumvent
OXPHOS for ATP generation; consistent with this, we
found that MiR-126 inhibited glucose uptake and gly-
colysis, thus restoring OXPHOS associated with a de-
crease in the mitochondrial redox activity (cf Fig. 3).
Taking into account the possibility that exosomes re-
leased by cancer cells present a major factor driving the
cancer phenotype, we can hypothesize that exosomes
from normal cells can be used as a vehicle for delivery of
anti-tumour factors. Since MiR-126 is secreted by ECs
by means of exosomes and since it can be readily inter-
nalised by recipient cells, we used exosomes as carriers
to deliver MiR-126 to cancer cells. Exosomal MiR-126
derived from HUVECs was found to interact with
MNSC cells, leading to increased MiR-126 levels,
whereby inducing anti-tumour responses such as inhib-
ition of cell proliferation and target gene modulation in-
cluding IRS1 and VEGF (cf Fig. 4).
To mimic the tumour stroma, a triple co-culture
model was performed. As previously reported [27], we
found that down-regulation of MiR-126 was related to
cancer stroma. This down-regulation can be attributed
to a cross-talk among cancer cells and the adjacent fi-
broblasts and angiogenic endothelial cells. Thus, target-
ing MiR-126 can be an innovative means to normalize
the aberrant vasculature in cancer environment. In this
context, exosomal MiR-126 significantly reduced VEGF
gene expression associated with reduced colony
formation, and inhibition of cell migration and prolifera-
tion (cf Fig. 5).
Involvement of MiR-126 in cancer biology is not lim-
ited to modulation of angiogenesis. Our results indicate
that this miRNA plays a role in cancer by altering sev-
eral cellular mechanisms of cancer pathogenesis. Exo-
somes containing miRNAs represent a promising new
therapeutic approach, since they play an important nat-
ural role in cellular processes combined with high stabil-
ity, tissue-specific expression, and secretion into body
fluids. The half-life of exosomes in the circulation is
greater than that of liposomes due to their endogenous
origin and unique surface composition. This enables
them to specifically bind to recipient cell receptors,
pointing to the possibility of utilising exosomes that spe-
cifically target a relevant cell type. Moreover, exosomes
are not immunogenic and can carry diverse cargo that
will not be ‘destroyed’ prior to delivery.
Conclusions
Our report suggests a potential role of circulating
MiR-126 as a biomarker to differentiate malignant types
from benign forms of nasal neoplastic pathologies. The
transfer of MiR-126 mediated by exosomes impacts on
protein regulation in acceptor cells, resulting in altered
cellular phenotypes. Thus, paracrine transfer of miRNAs,
as epitomised here by MiR-126, presents a new approach
to develop microRNA-based therapies for neoplastic
pathologies as well as improved diagnostic tools.
Additional files
Additional file 1: Figure S1. MiR-126 inhibits proliferation of cultured
malignant nasal-septum carcinoma (MNSC) cells. (A) MNSC cells were
treated with MiR-126 mimetic at increasing concentration, and MiR-126
content (insert) and cell proliferation were evaluated using the MTT assay.
(B) Cells were transfected with MiR-126 mimic (100 nM), plasmid MiR-126,
or antisense MiR-126 (antiMiR), and evaluated for their growth using the
MTT assay. The data shown are mean values ± S.D. derived from
three independent experiments. (TIF 886 kb)
Additional file 2: Figure S2. MiR-126 suppresses the malignant phenotype
of malignant nasal-septum carcinoma. (A) Colony-forming activity was
evaluated using cells transfected with MiR-126 (left panel) or MiR-126
mimetic (100 nM, right panel). (B) Morphology and metabolic stress
were evaluated as formation of acid vesicle (acridine orange staining)
and lipid droplets (LDs, Red-Oil O-staining) in plasmid-MiR-126
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transfected MNSC cells and in their parental counterparts. The scale
bar for all images equals 10 μm. The images (representative of three
independent experiments) visualized by fluorescent microscopy (Axiocam
MRc5, Zeiss, magnification 20×, 40× and 60×). (TIF 2484 kb)
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